$HALO · HALOZYME THERAPEUTICS, INC.
Halozyme completed its $1.5B convertible senior notes offering (1.50% due 2033), including the full $200M over-allotment. Net proceeds were ~$1,471.1M after fees. The company used ~$187.5M for capped call transactions (cap ~$208.39/share) and plans to retire ~$371.7M of existing 2027/2028 convertible notes at a combined cost of ~$652.5M. Remaining proceeds go to general corporate purposes.
- Issued $1.5B aggregate principal of 1.50% Convertible Senior Notes due 2033, including $200M from full exercise of initial purchasers' over‑
- Net proceeds were approximately $1,471.1M after discounts, commissions, and estimated expenses.
- Used ~$187.5M of net proceeds to fund capped call transactions with a cap price of ~$208.39/share (90% premium to spot at pricing).
- Expects to repurchase ~$151.7M of 0.25% 2027 Notes and $220.0M of 1.00% 2028 Notes for total costs of ~$217.0M and ~$435.5M respectively.
- Initial conversion rate: 7.1509 shares per $1,000 principal, equivalent to a conversion price of ~$139.84/share.
Stock is +3.30% in the regular session and +1.28% since filing, suggesting the market views the refinancing as constructive — extending maturities and reducing near-term dilution overhang from the 2027/2028 notes.
A $1.5B convertible refinancing that simultaneously extends debt maturities to 2033, retires near-term convertible overhang, and adds capped call protection at a 90% premium to spot.
Convertible-note refinancings remain a popular tool for biotech firms to manage balance sheets without immediate equity dilution; Halozyme's 1.50% coupon reflects strong credit access for a $13.66B market-cap company.
Capped call counterparties may hedge by trading HALO stock or derivatives, which could affect the stock price and conversion economics. The notes are unsecured and structurally subordinated to subsidiary liabilities.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.